Find-A-Study

AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (CTMS# 19-0169)

Purpose

Category

Cancers and Other Neoplasms

IRB Number: 20190839HU
NCT Number: -
Open to Enrollment: Yes
Sponsor: -

Study Contact

Principal Investigator
Anne-Marie Langevin

Regulatory Point of Contact
Virginia Diaz
210-562-9149
diazvr@uthscsa.edu

Regulatory Point of Contact
Jaclyn Hung
210-450-5358
hungj@uthscsa.edu

Eligibility

Eligible Ages: -
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Exclusion Criteria